Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 11, 2022
- Revision received September 14, 2022
- Published online March 2, 2023.
Article Versions
- previous version (September 22, 2022 - 12:25).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Amir Karimzadeh1,2,
- Matthias Heck3,
- Robert Tauber3,
- Karina Knorr1,
- Bernhard Haller4,
- Calogero D’Alessandria1,
- Wolfgang A. Weber1,
- Matthias Eiber*,1 and
- Isabel Rauscher*,1
- 1Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany;
- 2Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg–Eppendorf, Hamburg, Germany;
- 3Department of Urology, School of Medicine, Technical University of Munich, Munich, Germany; and
- 4Institute of AI and Informatics in Medicine, School of Medicine, Technical University of Munich, Munich, Germany
- For correspondence or reprints, contact Amir Karimzadeh (amir.karimzadeh{at}uke.de).
↵* Contributed equally to this work.
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
- Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer
- Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T
- [177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naive Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis
- The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- [177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naive Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis